X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013, Eloxx’s lead TURBO-ZM based molecule, for the treatment of rare dermatological and other diseases associated with nonsense mutations.
Lead Product(s): ZKN-013
Therapeutic Area: Genetic Disease Product Name: ZKN-013
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Eloxx Pharmaceuticals
Deal Size: $473.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 13, 2024
Details:
Through a license agreement, Almirall gets access of anti-IL-21 monoclonal antibody NN-8828, which it plans to develop for the treatment of immune inflammatory dermatological diseases.
Lead Product(s): NN-8828
Therapeutic Area: Dermatology Product Name: NN-8828
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 19, 2024
Details:
ALM223 (IL-2 mu-Fc) is a modified version of the protein IL-2 designed to selectively activate Regulatory T cells (Tregs). It is being evaluated in Phase I clinical studies for the patients related to Autoinmune dermatology.
Lead Product(s): ALM223
Therapeutic Area: Dermatology Product Name: ALM223
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
The collaboration aims to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer by leveraging etherna’s innovative mRNA/LNP technology platform and LNP formulations with Almirall’s leading expertise in dermatology.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Etherna
Deal Size: $327.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 12, 2023
Details:
Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
The partnership combines Absci’s de novo AI Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
Lead Product(s): De novo Therapeutic Antibody
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: AbSci
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 14, 2023
Details:
Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform technology to generate, develop and commercialize bispecific antibodies, for which Almirall will have exclusive global rights.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: EpimAb Biotherapeutics
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2023
Details:
Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
Through the acquisition, Almirall get exclusive rights to commercialize the Prometax (rivastigmine hydrogen tartrate), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Prometax
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: $64.2 million Upfront Cash: $48.1 million
Deal Type: Acquisition September 04, 2023
Details:
Ilumetri (tildrakizumab) is a humanized mAb that targets the p19 subunit of IL-23 and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. It is indicated for adults with moderate-to-severe plaque psoriasis.
Lead Product(s): Tildrakizumab
Therapeutic Area: Dermatology Product Name: Ilumetri
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
